Non-MHC-linked Th2 cell development induced by soluble protein administration predicts susceptibility to Leishmania major infection.
Continuous administration of soluble protein Ag followed by immunization with the same Ag in adjuvant results in the selective development of Ag-specific CD4+ Th2 cells in both normal and beta2-microglobulin-deficient BALB/c mice. In addition to chronic administration by mini-osmotic pump, single bolus i.p., but not i.v., injection of protein Ag induces Th2 cell expansion. Strong Th2 cell priming depends on a non-MHC-linked genetic polymorphism. It is observed in all congenic strains on BALB background tested, BALB/c, BALB/b, and BALB/k, but not in MHC-matched strains on disparate genetic background, B10.D2, C57BL/6, and C3H. DBA/2 mice appear to have an intermediate phenotype, as shown by their weaker capacity to mount Th2 responses as compared with BALB/c mice after soluble Ag administered by either mini-osmotic pumps or single bolus i.p. Conversely, induction of Th1 cell unresponsiveness by soluble protein is observed in any mouse strain tested, following any mode of Ag administration. These data demonstrate that non-MHC-linked genetic polymorphism controls the priming of Th2 but not the inhibition of Th1 cells induced by administration of soluble protein. The pattern of Th2 responses in these different strains is predictive of disease outcome following Leishmania major infection and supports the hypothesis that systemic Ag presentation in the absence of strong inflammatory signals may represent an important stimulus leading to selective Th2 cell development in susceptible mouse strains.
Guéry
J C
JC
Roche Milano Ricerche, Milan, Italy.
Galbiati
F
F
Smiroldo
S
S
Adorini
L
L
D000818:Animals; D000941:Antigens / Q000008:administration & dosage / Q000276:immunology*; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics; D004198:Disease Susceptibility; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D007111:Immunity, Cellular; D007114:Immunization / Q000379:methods*; D015918:Infusion Pumps, Implantable; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D018320:Leishmania major / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D008815:Mice, Inbred Strains; D009113:Muramidase / Q000008:administration & dosage / Q000276:immunology; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D010641:Phenotype; D011110:Polymorphism, Genetic; D013045:Species Specificity; D018417:Th1 Cells / Q000166:cytology / Q000276:immunology; D018418:Th2 Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D014373:Tuberculin / Q000008:administration & dosage / Q000276:immunology; D001613:beta 2-Microglobulin / Q000172:deficiency
D000941:Antigens; D014373:Tuberculin; D001613:beta 2-Microglobulin; D010047:Ovalbumin; D009113:Muramidase